Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 26 studies | 74% ± 16% | |
endothelial cell | 24 studies | 28% ± 12% | |
vein endothelial cell | 12 studies | 27% ± 6% | |
endothelial cell of artery | 11 studies | 27% ± 9% | |
endothelial cell of vascular tree | 11 studies | 27% ± 4% | |
capillary endothelial cell | 10 studies | 26% ± 8% | |
non-classical monocyte | 8 studies | 25% ± 7% | |
macrophage | 8 studies | 23% ± 8% | |
alveolar macrophage | 6 studies | 28% ± 9% | |
astrocyte | 6 studies | 32% ± 19% | |
oligodendrocyte | 4 studies | 29% ± 15% | |
conventional dendritic cell | 3 studies | 26% ± 8% | |
microglial cell | 3 studies | 18% ± 2% | |
dendritic cell | 3 studies | 21% ± 3% | |
granulocyte monocyte progenitor cell | 3 studies | 39% ± 18% | |
GABAergic neuron | 3 studies | 46% ± 29% | |
glutamatergic neuron | 3 studies | 46% ± 21% | |
interneuron | 3 studies | 53% ± 27% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1100.87 | 653 / 653 | 100% | 27.99 | 605 / 605 |
prostate | 100% | 806.03 | 244 / 245 | 100% | 16.68 | 500 / 502 |
breast | 100% | 1790.41 | 459 / 459 | 99% | 21.22 | 1108 / 1118 |
intestine | 100% | 848.03 | 964 / 966 | 98% | 17.04 | 519 / 527 |
lung | 100% | 2150.25 | 578 / 578 | 98% | 17.52 | 1135 / 1155 |
stomach | 97% | 538.82 | 350 / 359 | 100% | 17.03 | 285 / 286 |
bladder | 100% | 878.57 | 21 / 21 | 96% | 16.14 | 484 / 504 |
kidney | 99% | 552.94 | 88 / 89 | 96% | 30.74 | 864 / 901 |
uterus | 100% | 966.18 | 170 / 170 | 93% | 14.87 | 427 / 459 |
esophagus | 97% | 753.44 | 1397 / 1445 | 93% | 11.10 | 171 / 183 |
brain | 86% | 366.97 | 2285 / 2642 | 100% | 25.37 | 704 / 705 |
ovary | 100% | 588.06 | 180 / 180 | 76% | 8.33 | 328 / 430 |
pancreas | 73% | 226.62 | 241 / 328 | 100% | 25.72 | 178 / 178 |
skin | 72% | 432.61 | 1297 / 1809 | 97% | 14.87 | 460 / 472 |
adrenal gland | 64% | 184.01 | 165 / 258 | 99% | 22.28 | 228 / 230 |
liver | 11% | 29.12 | 24 / 226 | 93% | 11.63 | 378 / 406 |
adipose | 100% | 2084.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 69.39 | 29 / 29 |
spleen | 100% | 604.32 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.36 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 98% | 18.40 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 96% | 10.67 | 77 / 80 |
heart | 95% | 530.28 | 820 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 95% | 598.68 | 1264 / 1335 | 0% | 0 | 0 / 0 |
muscle | 88% | 349.11 | 705 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 86% | 839.40 | 795 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0038156 | Biological process | interleukin-3-mediated signaling pathway |
GO_0036016 | Biological process | cellular response to interleukin-3 |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0019955 | Molecular function | cytokine binding |
GO_0005515 | Molecular function | protein binding |
GO_0004896 | Molecular function | cytokine receptor activity |
GO_0004912 | Molecular function | interleukin-3 receptor activity |
Gene name | IL3RA |
Protein name | Interleukin 3 receptor subunit alpha Interleukin-3 receptor subunit alpha (IL-3 receptor subunit alpha) (IL-3R subunit alpha) (IL-3R-alpha) (IL-3RA) (CD antigen CD123) |
Synonyms | IL3R |
Description | FUNCTION: Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells . Ligand stimulation rapidly induces hetrodimerization with IL3RB, phosphorylation and enzyme activity of effector proteins such as JAK2 and PI3K that play a role in signaling cell proliferation and differentiation. Activation of JAK2 leads to STAT5-mediated transcriptional program (By similarity). . |
Accessions | ENST00000432757.6 P26951 ENST00000381469.7 [P26951-2] J3JS34 ENST00000711219.1 [P26951-1] ENST00000331035.10 [P26951-1] ENST00000711217.1 [P26951-2] ENST00000711218.1 |